SPRB
NASDAQSpruce Biosciences Inc.
Price$46.60-12.73 (-21.46%)
2026-05-042026-08-06
News · 26 weeks57+33%
2026-02-082026-08-02
Mix3090d
- Other10(33%)
- Insider8(27%)
- SEC Filings5(17%)
- Leadership4(13%)
- Analyst2(7%)
- Offering1(3%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Spruce Biosciences Inc.SCHEDULE 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
- PRSpruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical DevelopmentDr. Cohen Pfeffer Brings More Than a Decade of Clinical Development Leadership, Including Deep Experience with Enzyme Replacement Therapies for Rare Pediatric Neurodegenerative DisordersSpruce Biosciences, Inc. ("Spruce Biosciences" or "Spruce") (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development, effective today. Dr. Cohen Pfeffer brings more than a decade of biopharmaceutical industry experience spanning clinical development, product portfolio development and medica
- INSIDERSEC Form 4 filed by Chief Medical Officer Quartel Adrian W4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
- INSIDERSEC Form 3 filed by new insider Quartel Adrian W3 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Spruce Biosciences Inc.SCHEDULE 13G - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
- SECSpruce Biosciences Inc. filed SEC Form 8-K: Leadership Update8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
- PRSpruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical OfficerAccomplished Rare Disease Drug Developer Brings More Than 25 Years of Global Clinical Development and Medical Affairs Leadership, Including the Launch of Multiple Enzyme Replacement Therapies for Rare Pediatric and Genetic DisordersSpruce Biosciences, Inc. ("Spruce Biosciences" or "Spruce") (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective today. Dr. Quartel brings more than 25 years of experience in the international pharmaceutical industry, with senior roles spanning c
- ANALYSTB. Riley Securities initiated coverage on Spruce Biosciences with a new price targetB. Riley Securities initiated coverage of Spruce Biosciences with a rating of Buy and set a new price target of $160.00
- INSIDERCHIEF EXECUTIVE OFFICER Szwarcberg Javier B. was granted 266 shares, increasing direct ownership by 1% to 19,270 units (SEC Form 4)4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
- PRSpruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare SummitSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit, in a fireside chat hosted by Madison El-Saadi, Ph.D., Healthcare Research Analyst.The B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit will take place on July 16, 2026, at the InterContinental Boston hotel in Boston, MA.Participation in the summit is by invitation only. Investors interested in scheduling an in-person
- PRSpruce Biosciences Joins the Russell 3000® IndexInclusion Reflects Spruce’s Momentum as the Company Advances Toward a Planned Biologics License Application (BLA) Submission and Potential Commercial Launch of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB) Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has been added as a member of the Russell 3000® Index, effective with the opening of U.S. equity markets today, in connection with the 2026 Russell U.S. Indexes Reconstitution. The Russell 3000® Index measures the
- PRSpruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical AffairsDr. Jurecka Brings Deep Enzyme Replacement Therapy and Rare Disease Experience to Lead Medical Affairs and Scientific Engagement Ahead of Potential U.S. FDA Approval of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Agnieszka "AJ" Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs. "We are delighted to welcome AJ to the Spruce executive team. She is a rare combination of practic
- ANALYSTGuggenheim initiated coverage on Spruce Biosciences with a new price targetGuggenheim initiated coverage of Spruce Biosciences with a rating of Buy and set a new price target of $123.00
- PRSpruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate ControllerAppointments Further Strengthen Spruce's Commercial and Financial Capabilities as the Company Approaches a Potential U.S. FDA Approval and Commercial Launch of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointments of Eric Jordan as Vice President, Marketing and Tina Gullotta, CPA, as Vice President, Finance and Corporate Controller."We are delighted to welcome both Eric and Tina, two accomplished leaders
- PRSpruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS SymposiumData Highlight TA-ERT's Potential as the First Disease-Modifying Treatment Option for MPS IIIB, a Fatal Condition With No Approved Therapies Treatment With Weekly TA-ERT Demonstrated Rapid and Durable Normalization of CSF Heparan Sulfate Non-Reducing End (CSF HS-NRE), a Surrogate Endpoint Reasonably Likely to Predict Clinical Benefit TA-ERT Stabilized and Preserved Cognitive and Non-Cognitive Outcomes, Including Communication and Motor Skills, Over a Six-Year Period Relative to Natural History Patients Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unme
- PRSpruce Biosciences Announces Data Presentation at the 18th International MPS SymposiumNicole Muschol, M.D. to Present Long-Term Data on Tralesinidase Alfa (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data on the long-term administration of its tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB) will be presented at the 18th International MPS & Related Lysosomal Diseases Symposium, taking place June 4-7, 2026 in Florence, Italy. International MPS Symposium Presentation Details Title: Lo
- PRSpruce Biosciences to Participate in Upcoming Conferences in JuneSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that members of the management team will present and participate in one-on-one meetings at upcoming conferences taking place in June. Jefferies Global Healthcare Conference Date and Time: June 4, 2026, at 11:05 a.m. ET Format: Presentation and 1x1 meetings Location: New York Interested parties can access the live webcast for the Jefferies Global Healthcare Conference on the events section of the Company's website. An archived copy of the webcast will be available for appr
- INSIDERSEC Form 4 filed by Director Spiegelman Daniel K4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
- INSIDERSEC Form 4 filed by Director Simpson Camilla V4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
- INSIDERSEC Form 4 filed by Director Barretto-Ko Percival4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
- INSIDERSEC Form 4 filed by Executive Chairman Grey Michael G4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
- INSIDERSEC Form 4 filed by Director Walbert Keli4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
- SECSpruce Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Spruce Biosciences Inc.SCHEDULE 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Spruce Biosciences Inc.SCHEDULE 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
SPRB FAQ
7 questionsWhat does Spruce Biosciences Inc. do?
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). It offers tildacerfont, which is in Phase II clinical trial for children with classic CAH; and for females with polycystic ovary syndrome. In addition, it is involved in developing CAHmelia-203 which is in Phase 2b clinical trial for adult patients with classic CAH...Where does SPRB stock trade?
Spruce Biosciences Inc. (SPRB) is listed on NASDAQ.What sector and industry is SPRB in?
Spruce Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Spruce Biosciences Inc. go public?
Spruce Biosciences Inc. (SPRB) completed its IPO in 2020.What are analysts saying about SPRB?
Spruce Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from B. Riley Securities: Buy on 2026-07-13.What companies are similar to SPRB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SPRB side-by-side with any of them on Quantisnow.How can I track SPRB on Quantisnow?
Quantisnow aggregates Spruce Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SPRB to receive live email and push alerts on every new disclosure.